PharmaTher Applauds FDA's Commissioner's National Priority Voucher Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505 Focus, and Upside from Strategic ANDA Sale Biotech Investing
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors Biotech Investing
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer Biotech Investing
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome Biotech Investing
HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer Biotech Investing
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")
